After the extended acceptance period ending July 9 2002, Nobel Biocare Holding AG now owns approximately 99% of the shar

After the extended acceptance period ending July 9 2002, Nobel Biocare Holding AG now owns approximately 99% of the shares of Nobel Biocare AB Owning 99% of the shares in Nobel Biocare AB, Nobel Biocare Holding AG completes the offer to acquire all the outstanding shares of Nobel Biocare AB. The board of Nobel Biocare Holding AG has therefore decided to initiate a delisting of Nobel Biocare AB's shares (UNOB.ST) from the Stockholm Stock Exchange (Stockholmsbörsen), with last trading day 18th of July 2002. The compulsory acquisition procedure to acquire the remaining approximately 1% of the shares of Nobel Biocare AB will be initiated in January 2003. Nobel Biocare Holding AG's shares are listed on the SWX Swiss Exchange (NOBE.S) and the Stockholm Stock Exchange (NOBE.ST). On both these stock exchanges Nobel Biocare Holding AG ranks among the top 30 companies according to its market value and is a member of the respective stock indices. Gothenburg, 12 July 2002 Nobel Biocare Holding AG For further information: Harrieth Sundaeus, Nobel Biocare Holding AG, tel. +46 31 81 88 48, mobile +46 708 81 88 48 Michaela Ahlberg, Nobel Biocare Holding AG, tel. +46 31 81 88 29, mobile +46 708 81 88 29. Copies of this press release are not being, and must not be, mailed or otherwise distributed or sent in or into Australia or Japan. The Offer will and is not to be made in these countries. Statements made in this press release that relate to future events, performance or financial results of Nobel Biocare are forward-looking statements which involve uncertainties that could cause actual events, performance or results to materially differ. Nobel Biocare undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statement should be read in conjunction with the additional information about risks and uncertainties set forth in Nobel Biocare's annual reports and in the Offer Document dated 27 May 2002. Nobel Biocare is an innovative, medical devices company, whose core business comprises dental implants and dental prosthetics. The company's product systems for dental implants, Brånemark System® and Replace(TM), are world leaders and have a global market share of around 38%. The company's other product line, Procera®, is a unique, IT-based process for the industrial production of dental prosthetics. The system has been launched very successfully in more than 35 countries in North America, Europe, South East Asia and South America. Nobel Biocare has around 1,300 employees and, in 2001 net sales totaled SEK 2 663 million. www.nobelbiocare.com ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2002/07/12/20020712BIT00060/wkr0001.doc http://www.waymaker.net/bitonline/2002/07/12/20020712BIT00060/wkr0002.pdf